<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628783</url>
  </required_header>
  <id_info>
    <org_study_id>2012-002476-14</org_study_id>
    <nct_id>NCT01628783</nct_id>
  </id_info>
  <brief_title>Sequence Towards Remission in Depression</brief_title>
  <acronym>STRIDE</acronym>
  <official_title>Sequence Towards Remission in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jesper Ekelund</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators use clinical, biological and imaging markers to develop
      predictive markers for remission from depression. The investigators compare individuals who
      have received placebo to individuals who have received 10 mg of escitalopram for one week. In
      this double-blind, randomized study the investigators a) compare the groups to observe the
      short-term effects of escitalopram and b) study the predictive value of these observations
      with respect to remission. Measures include, but are not restricted to, limbic emotional
      reactivity as assessed by fMRI, emotional processing, emotional memory, autobiographical
      memory.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Åsberg rating scale</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microgranular cellulose in gelatine capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram in gelatine capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram 10 mg</intervention_name>
    <description>orally once daily</description>
    <arm_group_label>Escitalopram 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive disorder with current major depressive episode according to a
             SCID-I/P interview

          -  Montgomery-Åsberg depression rating score 15-30

          -  Age 18-60

        Exclusion Criteria:

          -  Borderline, schizoid or schizotypal personality, bipolar or any psychotic disorder

          -  Primary diagnosis is anxiety disorder: 300.00, .01, .02, .21, .22, .29, .23, .3,
             309.81, 308.3, 293.89

          -  Significant current suicidal ideation, or history of a suicide attempt

          -  Lifetime substance dependence; Last-year substance abuse; Last month over 24/16
             standard doses of alcohol/week; Lifetime use of illicit substances &gt; x5; Any illicit
             substance use in last month

          -  Depressive disorder due to medical condition or chemical substance

          -  Antidepressant medication use in last 4 months

          -  Severe, unstable somatic illness

          -  Use of antipsychotics, mood stabilizers, systemic corticosteroids, β-blockers or
             daytime benzodiazepines (a small dose of ≤10mg zolpidem once daily is permissible)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erkki Isometsä, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesper Ekelund, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesper Ekelund, MD-PhD</last_name>
    <phone>+358503317987</phone>
    <email>Jesper.Ekelund@helsinki.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erkki Isometsa, MD-PhD</last_name>
    <phone>+35894711</phone>
    <email>Erkki.Isometsa@helsinki.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Psychiatry Centre</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Ekelund, MD-PhD</last_name>
      <phone>+358503317987</phone>
      <email>Jesper.Ekelund@helsinki.fi</email>
    </contact>
    <contact_backup>
      <last_name>Emma Komulainen, MD</last_name>
      <phone>+358465260387</phone>
      <email>Emma.Komulainen@helsinki.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2012</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Jesper Ekelund</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>emotional processing</keyword>
  <keyword>fMRI</keyword>
  <keyword>autobiographic memory</keyword>
  <keyword>moderator of treatment response</keyword>
  <keyword>mediator of treatment response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

